The global medical information market size is calculated at USD 3.20 billion in 2025 and is forecasted to reach around USD 6.04 billion by 2034, accelerating at a CAGR of 7.32% from 2025 to 2034. The North America medical information market size surpassed USD 1.16 billion in 2024 and is expanding at a CAGR of 7.49% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Medical Information Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Medical Information Market, by Service Provider
8.1.1. In House
8.1.1.1. Market Revenue and Forecast
8.1.2. Contract Outsourcing
8.1.2.1. Market Revenue and Forecast
9.1. Medical Information Market, by Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Neurology
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiology
9.1.3.1. Market Revenue and Forecast
9.1.4. Immunology
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Medical Information Market, by Product Life Cycle
10.1.1. Pre-clinical
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinical
10.1.2.1. Market Revenue and Forecast
10.1.3. Post-market Approval
10.1.3.1. Market Revenue and Forecast
11.1. Medical Information Market, by Company Size
11.1.1. Small
11.1.1.1. Market Revenue and Forecast
11.1.2. Medium
11.1.2.1. Market Revenue and Forecast
11.1.3. Large Scale
11.1.3.1. Market Revenue and Forecast
cast
12.1. Medical Information Market, by End-use
12.1.1. Pharmaceuticals
12.1.1.1. Market Revenue and Forecast
12.1.2. Biotechnology Companies
12.1.2.1. Market Revenue and Forecast
12.1.3. Medical Device Manufacturers
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service Provider
13.1.2. Market Revenue and Forecast, by Therapeutic Area
13.1.3. Market Revenue and Forecast, by Product Life Cycle
13.1.4. Market Revenue and Forecast, by Company Size
13.1.5. Market Revenue and Forecast, by End-use
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service Provider
13.1.6.2. Market Revenue and Forecast, by Therapeutic Area
13.1.6.3. Market Revenue and Forecast, by Product Life Cycle
13.1.6.4. Market Revenue and Forecast, by Company Size
13.1.6.5. Market Revenue and Forecast, by End-use
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Service Provider
13.1.7.2. Market Revenue and Forecast, by Therapeutic Area
13.1.7.3. Market Revenue and Forecast, by Product Life Cycle
13.1.7.4. Market Revenue and Forecast, by Company Size
13.1.7.5. Market Revenue and Forecast, by End-use
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service Provider
13.2.2. Market Revenue and Forecast, by Therapeutic Area
13.2.3. Market Revenue and Forecast, by Product Life Cycle
13.2.4. Market Revenue and Forecast, by Company Size
13.2.5. Market Revenue and Forecast, by End-use
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service Provider
13.2.6.2. Market Revenue and Forecast, by Therapeutic Area
13.2.6.3. Market Revenue and Forecast, by Product Life Cycle
13.2.7. Market Revenue and Forecast, by Company Size
13.2.8. Market Revenue and Forecast, by End-use
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service Provider
13.2.9.2. Market Revenue and Forecast, by Therapeutic Area
13.2.9.3. Market Revenue and Forecast, by Product Life Cycle
13.2.10. Market Revenue and Forecast, by Company Size
13.2.11. Market Revenue and Forecast, by End-use
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service Provider
13.2.12.2. Market Revenue and Forecast, by Therapeutic Area
13.2.12.3. Market Revenue and Forecast, by Product Life Cycle
13.2.12.4. Market Revenue and Forecast, by Company Size
13.2.13. Market Revenue and Forecast, by End-use
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service Provider
13.2.14.2. Market Revenue and Forecast, by Therapeutic Area
13.2.14.3. Market Revenue and Forecast, by Product Life Cycle
13.2.14.4. Market Revenue and Forecast, by Company Size
13.2.15. Market Revenue and Forecast, by End-use
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service Provider
13.3.2. Market Revenue and Forecast, by Therapeutic Area
13.3.3. Market Revenue and Forecast, by Product Life Cycle
13.3.4. Market Revenue and Forecast, by Company Size
13.3.5. Market Revenue and Forecast, by End-use
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service Provider
13.3.6.2. Market Revenue and Forecast, by Therapeutic Area
13.3.6.3. Market Revenue and Forecast, by Product Life Cycle
13.3.6.4. Market Revenue and Forecast, by Company Size
13.3.7. Market Revenue and Forecast, by End-use
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service Provider
13.3.8.2. Market Revenue and Forecast, by Therapeutic Area
13.3.8.3. Market Revenue and Forecast, by Product Life Cycle
13.3.8.4. Market Revenue and Forecast, by Company Size
13.3.9. Market Revenue and Forecast, by End-use
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service Provider
13.3.10.2. Market Revenue and Forecast, by Therapeutic Area
13.3.10.3. Market Revenue and Forecast, by Product Life Cycle
13.3.10.4. Market Revenue and Forecast, by Company Size
13.3.10.5. Market Revenue and Forecast, by End-use
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service Provider
13.3.11.2. Market Revenue and Forecast, by Therapeutic Area
13.3.11.3. Market Revenue and Forecast, by Product Life Cycle
13.3.11.4. Market Revenue and Forecast, by Company Size
13.3.11.5. Market Revenue and Forecast, by End-use
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service Provider
13.4.2. Market Revenue and Forecast, by Therapeutic Area
13.4.3. Market Revenue and Forecast, by Product Life Cycle
13.4.4. Market Revenue and Forecast, by Company Size
13.4.5. Market Revenue and Forecast, by End-use
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service Provider
13.4.6.2. Market Revenue and Forecast, by Therapeutic Area
13.4.6.3. Market Revenue and Forecast, by Product Life Cycle
13.4.6.4. Market Revenue and Forecast, by Company Size
13.4.7. Market Revenue and Forecast, by End-use
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service Provider
13.4.8.2. Market Revenue and Forecast, by Therapeutic Area
13.4.8.3. Market Revenue and Forecast, by Product Life Cycle
13.4.8.4. Market Revenue and Forecast, by Company Size
13.4.9. Market Revenue and Forecast, by End-use
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service Provider
13.4.10.2. Market Revenue and Forecast, by Therapeutic Area
13.4.10.3. Market Revenue and Forecast, by Product Life Cycle
13.4.10.4. Market Revenue and Forecast, by Company Size
13.4.10.5. Market Revenue and Forecast, by End-use
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service Provider
13.4.11.2. Market Revenue and Forecast, by Therapeutic Area
13.4.11.3. Market Revenue and Forecast, by Product Life Cycle
13.4.11.4. Market Revenue and Forecast, by Company Size
13.4.11.5. Market Revenue and Forecast, by End-use
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service Provider
13.5.2. Market Revenue and Forecast, by Therapeutic Area
13.5.3. Market Revenue and Forecast, by Product Life Cycle
13.5.4. Market Revenue and Forecast, by Company Size
13.5.5. Market Revenue and Forecast, by End-use
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service Provider
13.5.6.2. Market Revenue and Forecast, by Therapeutic Area
13.5.6.3. Market Revenue and Forecast, by Product Life Cycle
13.5.6.4. Market Revenue and Forecast, by Company Size
13.5.7. Market Revenue and Forecast, by End-use
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service Provider
13.5.8.2. Market Revenue and Forecast, by Therapeutic Area
13.5.8.3. Market Revenue and Forecast, by Product Life Cycle
13.5.8.4. Market Revenue and Forecast, by Company Size
13.5.8.5. Market Revenue and Forecast, by End-use
14.1. Black Rock
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. UTI Mutual Fund
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Morgan Stanley
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. PIMCO
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. DSP Mutual Fund
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Trustee
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. JPMorgan Chase & Co
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Capital Group
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Vanguard
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample